When was Somaserve founded?

Somaserve was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Somaserve located?

Somaserve is headquartered in Cambridge, United Kingdom.

Who is the current CEO of Somaserve?

Francesca Crawford of Somaserve. They are also an angel investors in 1 startup.

Which legal entities is Somaserve associated with?

Somaserve is associated with SomaServe Ltd.

How many employees does Somaserve have?

As of Dec 31, 2021, the latest employee count at Somaserve is 5.

Is Somaserve a funded company?

Somaserve is a funded company, having raised a total of $2.94M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 2019.

When was the latest funding round of Somaserve?

Somaserve's latest funding was a $***** Series A round on Feb 22, 2021, with participation from 1 investor. Its primary sector is Life Sciences Platforms and Tools. In United Kingdom, the Life Sciences Platforms and Tools sector has seen $124M in funding in 2026 to date.

Where does Somaserve rank among its competitors?

Somaserve ranks 736th amongst 2190 active competitors, of which 523 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Life Biosciences, which secured $80M in Apr, 2026.

Who are the top competitors of Somaserve?

Somaserve's top competitors include Synthego, Liquidia and Antheia. Among them, Life Biosciences secured the most recent funding round in April, 2026.

Somaserve - 2026 Company Profile, Team, Funding, Competitors & Financials

Somaserve is a series A company based in Cambridge (United Kingdom), founded in 2018. It operates as a Developer of cell imaging and bio nanoparticles. Somaserve has raised $2.94M in funding from o2h ventures. The company has 2190 active competitors, including 523 funded and 364 that have exited. Its top competitors include companies like Synthego, Liquidia and Antheia.

Company Details

Developer of cell imaging and bio nanoparticles. The company has developed its polyNaut technology to image live cells that use amphiphilic block-based polymers composed of GRAS or metabolizable materials to create bionic nanoparticles for cytosolic release of drugs, proteins, peptides, nucleic acids, and small nanoparticles.

Website: somaserve.com
Email ID: *****@somaserve.com

Key Metrics

Founded Year

2018

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$2.94M in 2 rounds

Latest Funding Round

Series A, Feb 22, 2021, $*****

Investors

o2h ventures & 2 more

Ranked

736^th among 2190 active competitors

Employee Count

5 as on Dec 31, 2021

Similar Companies

Synthego & 2976 more

View Somaserve's full profile

Somaserve is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SomaServe Ltd CIN: 11617905 , United Kingdom, Active	Oct 10, 2018	-	5 (As on Dec 31, 2021)

Somaserve has raised a total funding of $2.94M over 2 rounds. Its first funding round was on Jul 2019. Its latest funding round was a Series A round on Feb 22, 2021 for $*****. 1 investor participated in its latest round. Somaserve has 3 institutional investors.

Here is the list of recent funding rounds of Somaserve:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 22, 2021	7651482	Series A	3958916	8998888	7293072	2257624
Jul 2019	6127354	Seed	7724815	3174165	o2h ventures	Abcam & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Somaserve's funding rounds and investors

Somaserve's employee count trend

Somaserve has 5 employees as of Dec 21. The total employee count is the same as what it was in Dec 20. Here is Somaserve's employee count trend over the years:

Uncover Somaserve's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Somaserve include Synthego, Liquidia and Antheia. Here is the list of Top 10 competitors of Somaserve, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
2nd	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, New Enterprise Associates & 18 others	68/100
3rd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
4th	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
5th	Acorda 1995, Ardsley (United States), Acquired	Developer of therapies that restore neurological function	$66.5M	Abn Amro, J P Morgan & 16 others	66/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Genedit 2016, Berkeley (United States), Series B	Developer of drug delivery system for genetic medicines	$93.5M	IMM Investment, SK & 20 others	64/100
8th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Fidelity Investments, New Enterprise Associates ... & 14 others	64/100
9th	Life Biosciences 2017, Boston (United States), Series D	Biotechnology pioneering cellular rejuvenation therapies to reverse and prevent aging diseases	$261M	Alpha Wave Global, Globalive Capital & 12 others	64/100
10th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Bpifrance & 13 others	63/100
736th	Somaserve 2018, Cambridge (United Kingdom), Series A	Developer of cell imaging and bio nanoparticles	$2.94M	Abcam, o2h ventures & 1 others	31/100